APGE logo

APOGEE THERAPEUTICS INC

APGENASDAQ
🏆 #981 by market capEarnings Nov 9US Equity
$952.29▲ $18.76 (+1.97%)
Simulated price
🔔
Track APGE
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 2.0%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$8.36B
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
64
Fair
No chart data available for APGE.

Trading Snapshot

Day Range
$949.04 – $967.63
52-Week Range
$35.39 – $135.09
Volume
$3.30B
Avg Volume
$2.87B
Shares Outstanding
61.9M
Next Earnings
Nov 10, 2026

Fundamentals Snapshot

Annual Revenue
$526M
Last Q Revenue
$135M
P/E Ratio
-31.1
P/S Ratio
0.0x
EPS (TTM)
$-3.90
Dividend Yield
0.00%
Dilution (1yr)
+10.0%

Why Investors Own APGE

  • ✓High-growth profile — revenue up +37.4% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 67% gross margin and 24% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

APGE logo

APOGEE THERAPEUTICS INC

APGE
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$286M▲ +31.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$233M▲ +35.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
60.7M▲ +10.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$123M▼ −$7M YoY
StockOtter · stockotter.space

About APOGEE THERAPEUTICS INC

Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
64/100

Analyst Price Target

ⓘ
Average Target
$1,163.38
▲ +22.2% Upside
High Target$1,397.40
Low Target$1,002.52
Based on 20 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

APOGEE THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift APGE price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

APOGEE THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.